Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Big Retailers Pull Sales of Weight-Loss Supplements With Dangerous Chemical

By Pharmaceutical Processing | April 10, 2015

After controversy has swirled for days around a group of weight-loss supplements containing a potentially dangerous chemical, many big retailers have pulled the product from their shelves.

The supplements in question include the ingredient acacia rigidula, a plant that contains an amphetamine-like stimulant called BMPEA. Though BMPEA has never been rigorously studied in humans, many health officials are worried the powerful stimulant could have side effects like other amphetamines including increased blood pressure, sleep troubles, cardiovascular complications, suppressed appetite and addiction.

Pressure on U.S. retailers to respond to the issue began mounting just days ago when a study revealed that many popular supplements — including Jet Fuel T-300, Yellow Scorpion, Black Widow and several others — contained BMPEA.

Yesterday, Vitamin Shoppe announced it would stop selling these supplements. Another supplement retailer, VitaCost, has followed suit.

But the issue doesn’t just raise concerns over BMPEA — it’s also triggered fresh scrutiny of the Food and Drug Administration.

According to several reports, the FDA documented the presence of BMPEA in supplements two years ago. While health authorities in Canada pulled the supplements from retailers’ shelves in December, FDA officials in the U.S. failed to give a health warning to consumers or recall any products. In its review of the products, the FDA said the stimulant “does not identify a specific safety concern.”

The situation has triggered a new wave of criticisms over the FDA’s role in the $33 billion-a-year supplement industry. Because of how supplements are classified, they aren’t subject to the same level of scrutiny as pharmaceuticals or food, leading to more lax oversight of their safety.

According to the New York Times:

“[Supplements] do not have to undergo federal reviews of their safety or effectiveness before they are sold to the public, and as a result tainted supplements are usually pulled from the market only after consumers are harmed.”

The same report also details how two of the top officials now overseeing supplement regulation at the FDA are former leaders of the supplement industry’s largest trade and lobbying group. While some have called the situation a clear conflict of interest, an FDA official said that having the expertise in the agency has been a benefit.

Meanwhile, other players in the field have been working to create a framework for stricter oversight of supplements. Last week a group of attorneys general asked Congress to provide the FDA more authority to regulate supplements. And after being accused of selling contaminated herbal supplements, GNC agreed to more extensive testing of its products.

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE